Logo image of SNDL

SNDL INC (SNDL) Stock Fundamental Analysis

NASDAQ:SNDL - Nasdaq - CA83307B1013 - Common Stock - Currency: USD

1.495  +0.02 (+1.01%)

Fundamental Rating

3

SNDL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. SNDL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNDL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SNDL had negative earnings in the past year.
In the past year SNDL had a positive cash flow from operations.
SNDL had negative earnings in each of the past 5 years.
In the past 5 years SNDL reported 4 times negative operating cash flow.
SNDL Yearly Net Income VS EBIT VS OCF VS FCFSNDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a decent Return On Assets value of -7.03%, SNDL is doing good in the industry, outperforming 73.23% of the companies in the same industry.
SNDL has a Return On Equity of -8.36%. This is in the better half of the industry: SNDL outperforms 78.79% of its industry peers.
Industry RankSector Rank
ROA -7.03%
ROE -8.36%
ROIC N/A
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
SNDL Yearly ROA, ROE, ROICSNDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SNDL's Gross Margin of 26.11% is in line compared to the rest of the industry. SNDL outperforms 52.02% of its industry peers.
SNDL's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SNDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
SNDL Yearly Profit, Operating, Gross MarginsSNDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNDL has about the same amount of shares outstanding.
SNDL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SNDL has an improved debt to assets ratio.
SNDL Yearly Shares OutstandingSNDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
SNDL Yearly Total Debt VS Total AssetsSNDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

SNDL has an Altman-Z score of 1.02. This is a bad value and indicates that SNDL is not financially healthy and even has some risk of bankruptcy.
SNDL's Altman-Z score of 1.02 is fine compared to the rest of the industry. SNDL outperforms 63.64% of its industry peers.
SNDL has a debt to FCF ratio of 3.47. This is a good value and a sign of high solvency as SNDL would need 3.47 years to pay back of all of its debts.
SNDL has a better Debt to FCF ratio (3.47) than 89.90% of its industry peers.
SNDL has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SNDL (0.10) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 3.47
Altman-Z 1.02
ROIC/WACCN/A
WACC8.23%
SNDL Yearly LT Debt VS Equity VS FCFSNDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

SNDL has a Current Ratio of 5.10. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
SNDL has a better Current ratio (5.10) than 73.74% of its industry peers.
SNDL has a Quick Ratio of 3.67. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
SNDL has a better Quick ratio (3.67) than 63.13% of its industry peers.
Industry RankSector Rank
Current Ratio 5.1
Quick Ratio 3.67
SNDL Yearly Current Assets VS Current LiabilitesSNDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

SNDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.64%, which is quite impressive.
SNDL shows a decrease in Revenue. In the last year, the revenue decreased by -1.35%.
EPS 1Y (TTM)85.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.01%
Revenue 1Y (TTM)-1.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.71%

3.2 Future

SNDL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.81% yearly.
SNDL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 80.96% yearly.
EPS Next Y40.31%
EPS Next 2Y33.31%
EPS Next 3Y23.32%
EPS Next 5Y13.81%
Revenue Next Year1181.89%
Revenue Next 2Y311.6%
Revenue Next 3Y157.37%
Revenue Next 5Y80.96%

3.3 Evolution

SNDL Yearly Revenue VS EstimatesSNDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
SNDL Yearly EPS VS EstimatesSNDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNDL. In the last year negative earnings were reported.
Also next year SNDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDL Price Earnings VS Forward Price EarningsSNDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SNDL is valued cheaper than 80.30% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNDL is valued cheaply inside the industry as 89.39% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.15
EV/EBITDA 17.3
SNDL Per share dataSNDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

SNDL's earnings are expected to grow with 23.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.31%
EPS Next 3Y23.32%

More info and screens

0

5. Dividend

5.1 Amount

SNDL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SNDL INC

NASDAQ:SNDL (4/25/2025, 3:39:09 PM)

1.495

+0.02 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-18 2025-03-18/bmo
Earnings (Next)05-01 2025-05-01
Inst Owners16.37%
Inst Owner Change-0.12%
Ins Owners0.33%
Ins Owner ChangeN/A
Market Cap384.65M
Analysts82.5
Price Target3.57 (138.8%)
Short Float %1.36%
Short Ratio2.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)153.92%
Min EPS beat(2)-37.25%
Max EPS beat(2)345.1%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.88%
Min Revenue beat(2)-0.07%
Max Revenue beat(2)1.83%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.69%
PT rev (3m)7.69%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-175%
EPS NY rev (3m)-175%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.32%
Revenue NY rev (3m)1.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF 12.15
P/OCF 9.71
P/B 0.47
P/tB 0.56
EV/EBITDA 17.3
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)0.12
FCFY8.23%
OCF(TTM)0.15
OCFY10.3%
SpS2.58
BVpS3.18
TBVpS2.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.03%
ROE -8.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.11%
FCFM 4.77%
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score8
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 3.47
Debt/EBITDA 5.1
Cap/Depr 19.43%
Cap/Sales 1.2%
Interest Coverage N/A
Cash Conversion 237.09%
Profit Quality N/A
Current Ratio 5.1
Quick Ratio 3.67
Altman-Z 1.02
F-Score8
WACC8.23%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.01%
EPS Next Y40.31%
EPS Next 2Y33.31%
EPS Next 3Y23.32%
EPS Next 5Y13.81%
Revenue 1Y (TTM)-1.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.71%
Revenue Next Year1181.89%
Revenue Next 2Y311.6%
Revenue Next 3Y157.37%
Revenue Next 5Y80.96%
EBIT growth 1Y45.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.49%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y278.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y429.85%
OCF growth 3YN/A
OCF growth 5YN/A